-
FDA Approves Duobrii (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis In Adults
drugs
April 28, 2019
FDA Approves Duobrii (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis In Adults.
-
FDA Approves of SKYRIZI™ for Moderate to Severe Plaque Psoriasis
americanpharmaceuticalreview
April 26, 2019
AbbVie announced the U.S. Food and Drug Administration (FDA) approved SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis in adults...
-
FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
drugs
April 25, 2019
FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis.
-
Skyrizi gets US approval for psoriasis
pharmatimes
April 24, 2019
AbbVie has announced the US Food and Drug Administration (FDA) approval of its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) for moderate to severe plaque psoriasis.
-
Alvotech, Fuji Pharma Sign Commercialization Agreement
contractpharma
April 15, 2019
For the exclusive partnership and supply to commercialize Alvotech’s ustekinumab biosimilar (Stelara) in Japan...
-
FDA Approves Novel TREMFYA One-Press Patient-Controlled Injector
americanpharmaceuticalreview
February 28, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) has approved TREMFYA® One-Press....
-
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
fiercepharma
January 13, 2019
Johnson & Johnson knows the immunology market is crowded. But that doesn’t mean it doesn’t still see tons of opportunity there.
-
Molecule discovery shows promise for psoriasis gene therapies
pharmatimes
December 24, 2018
Scientists at the University of Birmingham have announced the discovery of a protein that could hold the key to novel gene therapies for skin problems such as psoriasis.
-
Lilly's Taltz beats out AbbVie's megadrug Humira in psoriatic arthritis showdown
fiercepharma
December 19, 2018
What’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis (PsA).
-
Johnson & Johnson’s Tremfya tops Novartis blockbuster Cosentyx in head-to-head psoriasis showdown
fiercepharma
December 14, 2018
Johnson & Johnson’s Tremfya may have made its debut after key rivals, but it made waves Wednesday in the next-gen psoriasis field with Cosentyx-topping head-to-head data.